SCHEMBL7876539

SCHEMBL7876539

C[C@@H]([C@@H](CCc1ccccc1)C(=O)O)N(O)C=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 1/20 0.46
HTT P42858 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPK1 P28482 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ACE P12821 2/20 0.42
HSP90AA1 P07900 1/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.41
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7879161 0.92 GRIK1 (0.43) SMN1; SMN2KMT2AMEN1HTTHPGD
SCHEMBL4290877 0.92 GRIK1 (0.43) SMN1; SMN2KMT2AMEN1HTTHPGD
SCHEMBL7873373 0.90 LTB4R (0.44) KMT2AHPGDALDH1A1CYP2C9CYP2C19
SCHEMBL7876532 0.89 LTB4R (0.46)
SCHEMBL7953565 0.84 FDFT1 (0.43)
SCHEMBL7873355 0.81 ALOX5 (0.40)
SCHEMBL7874835 0.81 FFAR1 (0.44)
SCHEMBL7946312 0.81 DPP4 (0.38) KMT2A
SCHEMBL7874826 0.80 CTSB (0.42) SMN1; SMN2KMT2AMEN1HTTCYP2C9
SCHEMBL7431816 0.80 PPARA (0.47) KMT2AMEN1HTTTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6329400-B1 INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS GLAXO WELLCOME INC. 2001-12-11 US disclosed